Get started
Author

Hirohiko Fukiya

Institution: Ube (Japan)
Observed institution: Ube (Japan)
OpenAlex ID: A5073919436
Novel Keap1-Nrf2 Protein-Protein Interaction Inhibitor UBE-1099 Ameliorates Progressive Phenotype in Alport Syndrome Mouse Model
2021 · Shota Kaseda, Yuya Sannomiya, et al. · Kidney360 · 16
Efficacy of Nrf2 activation in a proteinuric Alport syndrome mouse model
2025 · Shota Kaseda, Jun Horizono, et al. · Life Science Alliance · 9
PDF
MO578: UBE-1099, A Novel Non-Covalent Keap1-NRF2 Inhibitor, Protects Against Renal Ischemia-Reperfusion Injury
2022 · Sayaka Ogi, Hidetoshi Sunamoto, et al. · Nephrology Dialysis Transplantation · 1
Kidney Protection by a Novel Keap1-Nrf2 Protein-Protein Interaction Inhibitor for a Mouse Model of Alport Syndrome
2024 · Jun Horizono, Shota Kaseda, et al. · Journal of the American Society of Nephrology
Efficacy of Keap1-Nrf2 protein-protein interaction inhibitor for glomerulosclerosis in mouse model of chronic kidney disease
2022 · Shota Kaseda, Yuya Sannomiya, et al. · Proceedings for Annual Meeting of The Japanese Pharmacological Society
PDF
Novel Keap-Nrf2 Protein-Protein Interaction Inhibitor UBE-1099 Ameliorates the Severity of Experimental Alport Syndrome
2021 · Shota Kaseda, Mary Ann Suico, et al. · Journal of the American Society of Nephrology
UBE-1099, a Novel Non-Covalent Keap1-Nrf2 Inhibitor, Protects Against Renal Ischemia-Reperfusion Injury via Nrf2 Activation
2021 · Sayaka Ogi, Hidetoshi Sunamoto, et al. · Journal of the American Society of Nephrology
Works count: 7
Citation count: 26
H-index: 2
I10-index: 1
Year
Topic
Type